



The Council on Radionuclides and Radiopharmaceuticals, Inc.

Michael J. Guastella, MS, MBA
Executive Director

500 North Capitol Street, NW
Suite 210
Washington, DC 20001-7407
(202) 547-6582
Fax: (202) 547-4658
michael.guastella@corar.org

DRAFT (4-1-18)

ISOTOPE SUPPLY COMMITTEE

Tuesday, December 5, 2017, 10:15 AM – 11:45 PM
Offices of Reed Smith; 1301 K Street, NW – East Tower, Washington, D.C.
Conference Rooms 10H & 10I
Dial-In Number: 1-800-730-9938; Access Code: 4149241

- I. Welcome**
The committee was called to order by Co-Chairs Ira Goldman and Roy Brown.
- II. Antitrust Guidance from Counsel (Andy Bernasconi)**
Andy Bernasconi, Reed Smith, CORAR Antitrust Counsel, addressed the members of the committee and reminded them of CORAR’s antitrust policy, their obligations as CORAR Members, and the potential repercussions to them, the association and their companies in the event of non-compliance. Counsel remained with the committee through the committee’s deliberations.
- III. Approval of the Minutes from the May 2, 2017 Committee Meeting**
A motion of approval was made by a Member of the Committee and the minutes of May 2, 2017 ISC Committee were approved as written.
- IV. 2017 Isotope Supply Committee Co-Chair Election Results**
Discussion: Michael Guastella announced that Roy Brown has been elected to serve another 2 year term as Co-Chair.
- V. Update on Administration and Congressional Issues (Jim Massie)**
Discussion: Jim Massie reviewed for the Committee the Federal issues that have warranted CORAR action over the last few months, including S. 512 (intended to ensure a new market for U.S. uranium miners); the National Defense Authorization Act; and the Energy and Water Appropriations bill.

CORAR has worked with Senator Barrasso (R-WY), to finalize language to address CORAR’s concerns. S. 512 was approved by the Senate Environment and Public Works Committee but has stalled.

In addition, CORAR worked with Congress on a variety of questions regarding the supply and production with medical isotopes. The final NDAA legislation contains a

provision requiring DOE to provide Congress a new report on the progress of eliminating the use of HEU from the production on medical isotopes. And the Energy and Water Appropriations legislation contains provisions to raise the US Government cost-share cap to provide additional funds (+\$10M) for each of the DOE cooperative agreement projects. Lastly, the Committee endorsed Annie Caputo to serve as a Commissioner to NRC. Caputo's nomination has passed out of Committee, but is being held up by Senator Heller (R-NV).

Action: CORAR formulate comments to provide to DOE to ensure that the report required by the NDAA legislation contains a balanced perspective.

VI. Mo-99 Update.....I. Goldman/ R. Brown

1. Implementation of AMIPA/ULTB Update and Status

The Committee took note of recent interactions with the Administration and Congressional Committees as previously described by J. Massie.

2. Publicly available new domestic Mo-99 production project updates from CORAR members (Nordion, Northstar, Northwest, and SHINE)

SHINE, Northstar, Northwest Medical Isotopes, and Nordion provided brief updates to the Committee.

3. Mo-99 Reviews (e.g., NSAC)

Roy Brown noted that the NSAC Mo-99 Subcommittee will be meeting in mid-December to carry-out the annual review of the DOE domestic Mo-99 program. A number of committee members indicated skepticism regarding the utility of the NSAC review, including its limited scope.

4. OECD/NEA High Level Group on Medical Radioisotopes Update

Roy Brown stated that the HLG-MR would be meeting in early February and the focus of the meeting will be the group's future after completion of the current fourth mandate including greater involvement of the OECD Health Directorate to study reimbursement issues.

5. EU Mo-99 Observatory/AIPES Update

Ira Goldman reviewed the EU Observatory and AIPES Security of Supply Working Group meetings which took place in Munich in October. The Observatory has been re-structured as most of the working groups have completed their work. There were also presentations on two on-going EU-studies, SAMIRA and SMER, both assessing the market and role of radioisotopes. It was noted that publicly-available information indicates there is a disruption in production by NTP. The AIPES Emergency Response Team (ERT) has been meeting to assess the situation and to develop mitigating measures.

6. IAEA Activities and Projects Update (e.g., Meeting on Global Capabilities for Production of Mo-99 Targets)

Ira Goldman briefly reviewed the meeting held in May, which was the continuation in a long series of meetings on LEU target conversion. Future plans for this meeting are not yet clear.

7. **9th ICI Meeting**

Ira Goldman reviewed the 9th ICI Conference which took place in November in Doha. The ongoing political situation in the Gulf negatively affected participation in the Conference. Ira provided an outline on panels and discussions, particularly the discussion on high-risk radioactive sources, which featured DOE and Nuclear Threat Initiative efforts to eliminate in the U.S. the use of cesium-137 sources for blood irradiation, replacing with x-ray. The committee needs to continue to monitor the DOE efforts related to source security as it is likely that the efforts to encourage alternative technologies will expand to Co-60 sources. The goal is to have the meeting every other year and the next one will be in 2019 in Malaysia.

8. **Joint National Academy of Sciences and Russian Academy of Sciences Mo-99 Study Symposium Update**

Roy provided a brief review of the meeting, stating that it was very well attended. Russian presentations put more emphasis on non-traditional approaches to Mo-99 production.

VII. New Business

The Committee briefly discussed the impact of Brexit and legislation pending in the UK's Parliament. The Committee is interested in further updates on these issues in the future.

VIII. Adjourn

The Committee adjourned at 11:43 am.

IX. Next Meeting – May 15, 2018